Helperby Therapeutics-Cadila Pharmaceuticals partnership has World’s First Antibiotic Resistance Breaker in Development
The Helperby Therapeutics-Cadila Pharmaceuticals partnership announced that potentially life-saving treatments are now in development – just six months after signing their agreement.
Helperby Therapeutics, a spin-out of St George’s University of London and one of the few pioneers globally working to overcome antibiotic resistance, has discovered that combining its patented resistance breakers with obsolete antibiotics can produce effective microbial kill rates with significantly lower or no toxicity to the patient.
The partnership is developing a potential treatment against the world’s most deadly superbugs, gram-negative carbapenem-resistant organisms. The last line of defence for patients critically ill with this deadly organism is colistin - an antibiotic with serious side effects and to which resistance is already beginning to emerge.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.